Sepsis steroid review leaves the best regimen unresolved
The review reports survival and organ-support benefits for selected regimens, while a key hydrocortisone mortality result rests on a single small trial.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This abstract-based review reported lower mortality and improvements in some measures of organ support with selected corticosteroid regimens. However, an emphasized hydrocortisone mortality finding came from a single small trial. The evidence described here does not establish an optimal regimen, and the abstract leaves important details of the reported comparisons unclear.
The abstract inconsistently labels a mortality measure as an odds ratio and RR, and omits its comparator. Several other estimates lack confidence intervals, preventing a clear assessment of their precision.
Different outcomes and regimens
The review examined mortality over shorter and longer periods, intensive-care stay, and time free from organ support. Different regimens were linked with different outcomes, so the abstract does not describe a uniformly superior treatment strategy.
A preliminary mortality signal
The authors explicitly describe the highlighted hydrocortisone mortality finding as preliminary because it relies on a small trial. That caution matters when interpreting the broader conclusion, which makes a more general claim about corticosteroid benefits.
The original publication
Corticosteroids for treating sepsis: A systematic review and network meta-analysis.
Luo X, Yang J, Zhang Z et al.
Respir Med · 2026
- PubMed ID
- 41865776
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.